Thyrocare Q1FY27: Revenue surges 24% to ₹240.02 Cr, PAT up 34% to ₹51.33 Cr
Thyrocare Technologies reported Q1FY27 results with consolidated revenue up 24% YoY to ₹240.02 Cr and PAT up 34% YoY to ₹51.33 Cr. The company processed 55.2 million tests, a 28% YoY increase. Thyrocare has expanded into Specialty Diagnostics, starting with Allergy and Genomics.
The strong financial performance, significant YoY growth in key metrics, and strategic expansion into specialty diagnostics are material positive developments for the company.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT, along with an increase in processed tests and expansion into new diagnostic areas.
Thyrocare Technologies Limited announced its unaudited financial results for the quarter ended June 30, 2026. The company reported a consolidated revenue of ₹240.02 crore, marking a significant 24% year-on-year growth. This strong performance was primarily driven by a 26% increase in the Pathology segment.
Consolidated EBITDA grew by an impressive 34% year-on-year to ₹77.27 crore, while Profit After Tax (PAT) also surged by 34% year-on-year to ₹51.33 crore. Thyrocare, recognized as India's largest diagnostic test volume processor, processed 55.2 million tests during the quarter, reflecting a robust 28% year-on-year growth.
The Pathology business demonstrated sustained traction, with franchise revenue increasing by 27% and partnership revenue by 26% year-on-year. The company also maintained its commitment to quality, reducing complaints per million tests to 3.1 (a 24% YoY decrease) with an Average Turnaround Time (ATAT) of 3.37 hours, positioning itself as India's first diagnostic chain to achieve this benchmark.
Thyrocare has embarked on its next growth phase by expanding into Specialty Diagnostics, commencing with Allergy and Genomics. This strategic move aims to build clinical trust through scientific rigor, uncompromising quality, and industry-leading turnaround times.
Rahul Guha, MD & CEO of Thyrocare Technologies Ltd, commented, “Thyrocare reported a strong performance this quarter, driven by continued focus on operational efficiency, network expansion, and value-driven diagnostics. During the period, we also strengthened our specialty portfolio with the addition of allergy testing and entry into genomics through the launch of NIPT, with a phased expansion of the test menu underway. Thyrocare continues to expand its reach in underserved regions and scale its franchise and partner network, while remaining committed to delivering high-quality, affordable healthcare services across India.”
What to do with a filing like this
Thyrocare Technologies Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Thyrocare Technologies Limited. Read the original for the full detail.